EichorEICHOR
Condition: Neuroendocrine Tumor Of The Lung Synced from ClinicalTrials.gov · August 08, 2026

Recruiting studies: Neuroendocrine Tumor Of The Lung

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Phase 1/Phase 2 · 13 location(s) · IDEAYA Biosciences · NCT07174583ALG-LungCancerRegistry (SAFRO2202)
Phase N/A · 21 location(s) · Société Algérienne de Formation et de Recherche en Oncologie · NCT07161882A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multi
Phase 1 · 69 location(s) · Shanghai Henlius Biotech · NCT07160335Promoting Immunotherapy Efficacy With Low-Dose Liver RT
NA · 1 location(s) · Jordan Kharofa · NCT07225036Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Phase 1 · 3 location(s) · BioEclipse Therapeutics · NCT04282044An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
Phase 1/Phase 2 · 3 location(s) · Beijing Tide Pharmaceutical Co., Ltd · NCT07371663A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · 165 location(s) · Turning Point Therapeutics, Inc. · NCT03093116Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembr
Phase 1/Phase 2 · 2 location(s) · Strand Therapeutics Inc. · NCT07751042START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Phase 1 · 7 location(s) · Valo Therapeutics Oy · NCT05492682A Study of IBI363 in Subjects with Advanced Solid Malignancies
Phase 2 · 9 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT06281678FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum
Phase 2 · 31 location(s) · Centre Leon Berard · NCT06393816The Florida ASCENT Study
NA · 1 location(s) · University of Florida · NCT07042243Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06228066Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuro
Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT06202066Risk Factors for Neuroendocrine Neoplasms
Phase N/A · 1 location(s) · Bavarian Cancer Registry · NCT06282016A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Phase 1/Phase 2 · 4 location(s) · OncoResponse, Inc. · NCT06090266A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Phase 1 · 10 location(s) · Compass Therapeutics · NCT06150664A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alon
Phase 1/Phase 2 · 67 location(s) · BioNTech SE · NCT07070232Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT05830058A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Phase 1 · 12 location(s) · Pliant Therapeutics, Inc. · NCT06270706Pan-tumor MRD Study
Phase N/A · 2 location(s) · Paradigm Health · NCT06605404A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S
Phase 2 · 57 location(s) · Bristol-Myers Squibb · NCT07492680A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/Phase 2 · 5 location(s) · 7 Hills Pharma, LLC · NCT06362369Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Phase 1/Phase 2 · 21 location(s) · Revolution Medicines, Inc. · NCT05379985Liquid Biopsy Evaluation and Repository Development at Princess Margaret
Phase N/A · 1 location(s) · University Health Network, Toronto · NCT03702309MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Phase 1 · 2 location(s) · Memgen, Inc. · NCT05076760Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04771520SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Phase 1 · 3 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT0751719818F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis
Phase N/A · 1 location(s) · Nanjing First Hospital, Nanjing Medical University · NCT06937112
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.